MSH|^~\&|HEXALIS|TEST|CERBA|EDS|20241023130932||ORU^R01^ORU_R01|202410231309321794|P|2.5.1|241023130932795||||FRA|8859/15|FR||05.00-104285^HEXALISPID|1||~C2050600022^^^HEXALIS&ETALON3_HEXATEST~278104410923680^^^ASIP-SANTE-INS-NIR&1.2.250.1.213.1.4.8&ISO^INS~C1061500007^^^HEXALIS&ETALON2_Q451^LOCAL~C3050300071^^^HEXALIS&ETALON3_QUALIF500^LOCAL||NEWLIFES^STEPHANIES^^^ME^^D~NEWLIFESD^STEPHANIE^STEPHANIE NATHALIE^^ME^^L|NEWLIFESD|19781024|F|||13 rue des champigons^b12^MARSEILLE^^13013^^^^99999||0102030405^^PH^^^^^^^^^+33601020304~+33601020304^^CP||||||||||INCONNU||1|||||||VALIORC|SC|C2121600013_FER^HEXALIS^ETALON3_QUALIF500|C2121600013_FER^HEXALIS^ETALON3_QUALIF500|C2121600013-1-0012^HEXALIS^ETALON3_QUALIF500|CM||^^^20221216171200||20221216170300|||SDPRE^Pr Prescripteur SD~DLX^Prescripteur DLXOBR|1|C2121600013_FER^HEXALIS^ETALON3_QUALIF500|C2121600013_FER^HEXALIS^ETALON3_QUALIF500|FER^FER^HEXALIS-ETALON3_QUALIF500|||20221216171200|||993010628||||20221216171200|||||||||||F|||||||||||20221216TQ1|||||||||ROBX|1|NM|FER--test^Fer^HEXALIS-ETALON3_QUALIF500^FER^Fer||150|µg/dL^^HEXALIS-ETALON3_QUALIF500|        50 à 167|N|||F|||20221216170354||JM^DR MARTIN Jean-PierreOBX|2|NM|FER-converti--test^Fer - converti^HEXALIS-ETALON3_QUALIF500^FER^Fer||26.9|¦mol/L^µmol/L^HEXALIS-ETALON3_QUALIF500|8,9 à 29,9|N|||F|||20221216170354||JM^DR MARTIN Jean-PierreORC|SC|C2121600013_ACE25^HEXALIS^ETALON3_QUALIF500|C2121600013_ACE25^HEXALIS^ETALON3_QUALIF500|C2121600013-1-0012^HEXALIS^ETALON3_QUALIF500|CM||^^^20221216171200||20221216170300|||SDPRE^Pr Prescripteur SD~DLX^Prescripteur DLXOBR|2|C2121600013_ACE25^HEXALIS^ETALON3_QUALIF500|C2121600013_ACE25^HEXALIS^ETALON3_QUALIF500|ACE25^A.C.E.^HEXALIS-ETALON3_QUALIF500|||20221216171200|||993010628||||20221216171200|||||||||||F|||||||||||20221216TQ1|||||||||ROBX|1|NM|ACE--test^A.C.E.^HEXALIS-ETALON3_QUALIF500^ACE^Antigène Carcino-embryonnaire||5.0|µg/L^^HEXALIS-ETALON3_QUALIF500|      Inf. à 5,0|N|||F|||20221216170354||JM^DR MARTIN Jean-Pierre